Table III.
Overall survival according to different prognostic factors in patients with advanced-stage mycosis fungoides and Sezary syndrome (univariate analysis)
| Characteristics | n (%) | Survival Median (range) | 5-year OS (%) | p-value |
|---|---|---|---|---|
| Age | 0.0004 | |||
| <70 years | 38 (50) | NA (4.2–NA) | 67 | |
| ≥70 years | 38 (50) | 31.2 (1.4–168) | 19 | |
| Sex | 0.80 | |||
| Male | 51 (67.1) | – | – | |
| Female | 25 (32.9) | – | – | |
| Stage | 0.09 | |||
| IIB | 29 (38.1) | 118.7 (36.5–168.0) | 59.1 | |
| III | 20 (26.3) | 45.7 (1.4–179.6) | 34.9 | |
| IV | 27 (35.6) | 31.2 (3.0–149.1) | 35.3 | |
| III/IV (vs IIB) | 47 (61.8) | – | – | 0.04 |
| ECOG-PS | 0.0001 | |||
| 2 | 62 (81.6) | 90.3 (1.4–179.6) | 54.9 | |
| ≥2 | 14 (18.4) | 8.8 (1.5–42.6) | 0 | |
| Previous early-stage phase | 0.13 | |||
| Yes | 45 (59.2) | – | – | |
| No | 31 (40.8) | – | – | |
| LDHa | 0.67 | |||
| Normal | 19 (32.2) | – | – | |
| Elevated | 40 (67.8) | – | – | |
| LCT | 0.27 | |||
| Yes | 36 (47.4) | – | – | |
| No | 40 (52.6) | – | – | |
| CLIPi | 0.14 | |||
| 1 | 23 (30.3) | NA (4.2–60.2) | 63.8 | |
| 2 | 25 (32.9) | 47.0 (1.5–168.0) | 40.2 | |
| 3 | 28 (36.8) | 45.7 (1.4–179.6) | 30.0 | |
| CLIC index | 0.009 | |||
| 1 | 15 (25.4) | NA (5.5–127.8) | 60.4 | |
| 2 | 25 (42.4) | 58.3 (1.5–179.5) | 49.9 | |
| 3 | 19 (32.2) | 10.5 (1.4–118.7) | 23.2 | |
| 3 (vs 1–2) | – | – | – | 0.0025 |
a
Data missing for 17 patients.
OS: overall survival; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; LDH: lactate dehydrogenase; LCT: large cell transformation in skin; CLIPi: Cutaneous Lymphoma International Prognostic index; CLIC index: Cutaneous Lymphoma International Consortium prognosis index; HR: hazard ratio.